GENFIT (GNFT) Competitors $3.75 +0.03 (+0.81%) As of 08/8/2025 03:55 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GNFT vs. NUVB, QURE, PHAR, CRON, SION, ANAB, GHRS, DNA, NAGE, and TNGXShould you be buying GENFIT stock or one of its competitors? The main competitors of GENFIT include Nuvation Bio (NUVB), uniQure (QURE), Pharming Group (PHAR), Cronos Group (CRON), Sionna Therapeutics (SION), AnaptysBio (ANAB), GH Research (GHRS), Ginkgo Bioworks (DNA), Niagen Bioscience (NAGE), and Tango Therapeutics (TNGX). These companies are all part of the "pharmaceutical products" industry. GENFIT vs. Its Competitors Nuvation Bio uniQure Pharming Group Cronos Group Sionna Therapeutics AnaptysBio GH Research Ginkgo Bioworks Niagen Bioscience Tango Therapeutics GENFIT (NASDAQ:GNFT) and Nuvation Bio (NYSE:NUVB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk. Which has more risk & volatility, GNFT or NUVB? GENFIT has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500. Comparatively, Nuvation Bio has a beta of 1.35, suggesting that its share price is 35% more volatile than the S&P 500. Does the media refer more to GNFT or NUVB? In the previous week, Nuvation Bio had 8 more articles in the media than GENFIT. MarketBeat recorded 8 mentions for Nuvation Bio and 0 mentions for GENFIT. Nuvation Bio's average media sentiment score of 0.46 beat GENFIT's score of 0.00 indicating that Nuvation Bio is being referred to more favorably in the news media. Company Overall Sentiment GENFIT Neutral Nuvation Bio Neutral Do institutionals and insiders have more ownership in GNFT or NUVB? 2.2% of GENFIT shares are owned by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are owned by institutional investors. 4.2% of GENFIT shares are owned by company insiders. Comparatively, 29.9% of Nuvation Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is GNFT or NUVB more profitable? GENFIT has a net margin of 0.00% compared to Nuvation Bio's net margin of -1,413.43%. GENFIT's return on equity of 0.00% beat Nuvation Bio's return on equity.Company Net Margins Return on Equity Return on Assets GENFITN/A N/A N/A Nuvation Bio -1,413.43%-43.92%-37.93% Do analysts prefer GNFT or NUVB? GENFIT presently has a consensus target price of $13.00, suggesting a potential upside of 246.67%. Nuvation Bio has a consensus target price of $7.33, suggesting a potential upside of 218.84%. Given GENFIT's higher probable upside, equities analysts plainly believe GENFIT is more favorable than Nuvation Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GENFIT 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Nuvation Bio 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Which has better earnings & valuation, GNFT or NUVB? GENFIT has higher revenue and earnings than Nuvation Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGENFIT$76.77M2.44$1.63MN/AN/ANuvation Bio$7.87M99.44-$567.94M-$2.35-0.98 SummaryNuvation Bio beats GENFIT on 9 of the 15 factors compared between the two stocks. Get GENFIT News Delivered to You Automatically Sign up to receive the latest news and ratings for GNFT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GNFT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNFT vs. The Competition Export to ExcelMetricGENFITMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$190.01M$2.99B$5.52B$9.72BDividend YieldN/A2.42%4.60%4.12%P/E RatioN/A17.2130.0124.75Price / Sales2.44310.81450.0597.82Price / Cash54.3341.7736.7758.47Price / Book2.507.318.185.59Net Income$1.63M-$54.43M$3.26B$265.99M7 Day Performance-1.70%0.01%6.13%5.06%1 Month PerformanceN/A0.63%0.07%0.61%1 Year Performance-4.58%8.41%36.31%22.82% GENFIT Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNFTGENFIT1.578 of 5 stars$3.75+0.8%$13.00+246.7%-4.6%$190.01M$76.77M0.00120Gap UpHigh Trading VolumeNUVBNuvation Bio2.0022 of 5 stars$2.31+3.6%$7.17+210.2%-18.7%$758.79M$7.87M-0.9860News CoverageEarnings ReportAnalyst ForecastQUREuniQure2.5861 of 5 stars$13.77+0.6%$36.55+165.4%+85.7%$751.40M$27.12M-3.51500PHARPharming Group2.7681 of 5 stars$12.25+11.8%$30.00+144.9%+65.4%$750.92M$297.20M-94.23280High Trading VolumeCRONCronos Group1.1608 of 5 stars$2.02+3.6%N/A+4.5%$748.42M$117.61M15.54450News CoverageEarnings ReportAnalyst DowngradeAnalyst RevisionSIONSionna TherapeuticsN/A$17.12+1.2%$38.50+124.9%N/A$746.59MN/A0.0035Lockup ExpirationANABAnaptysBio2.1927 of 5 stars$24.23-1.9%$47.13+94.5%-36.4%$725.40M$91.28M-5.00100News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionGHRSGH Research2.7033 of 5 stars$13.44-2.2%$32.00+138.1%+23.4%$714.87MN/A-17.0110Positive NewsEarnings ReportDNAGinkgo Bioworks1.2476 of 5 stars$13.62+11.7%$8.50-37.6%N/A$713.50M$227.04M-1.49640News CoverageEarnings ReportGap UpNAGENiagen Bioscience1.2867 of 5 stars$9.64+6.6%$13.22+37.1%+253.8%$712.08M$99.60M56.71120News CoverageEarnings ReportAnalyst RevisionTNGXTango Therapeutics1.9625 of 5 stars$6.59+0.9%$10.50+59.3%-22.2%$707.81M$40.99M-5.4090News CoverageEarnings ReportAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies Nuvation Bio Alternatives uniQure Alternatives Pharming Group Alternatives Cronos Group Alternatives Sionna Therapeutics Alternatives AnaptysBio Alternatives GH Research Alternatives Ginkgo Bioworks Alternatives Niagen Bioscience Alternatives Tango Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNFT) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredGreen Light for These StocksGuess Who Washington Will Partner With Next? The U.S. government just made a bold $400 million move... beco...Stansberry Research | SponsoredAltucher: $900 to $108,000? Trump’s “Great Gain” Is HereJames Altucher says two recent events could trigger a historic wealth shift—one driven by a radical Trump poli...Paradigm Press | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 17th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GENFIT S.A. Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share GENFIT With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
